Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis

被引：44

作者：

Ebina, Kosuke ^{[1
]}

Hirao, Makoto ^{[2
]}

Tsuboi, Hideki ^{[3
]}

Nagayama, Yoshio ^{[4
]}

Kashii, Masafumi ^{[5
]}

Kaneshiro, Shoichi ^{[6
]}

Miyama, Akira ^{[2
]}

Nakaya, Hiroyuki ^{[7
]}

Kunugiza, Yasuo ^{[8
]}

Okamura, Gensuke ^{[3
]}

Etani, Yuki ^{[2
]}

Takami, Kenji ^{[2
]}

Goshima, Atsushi ^{[2
]}

Nakata, Ken ^{[9
]}

机构：

[1] Osaka Univ, Dept Musculoskeletal Regenerat Med, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan

[2] Osaka Univ, Dept Orthopaed Surg, Grad Sch Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan

[3] Osaka Rosai Hosp, Dept Orthopaed Surg, Kita Ku, 1179-3 Nagasone Cho, Sakai, Osaka 5918025, Japan

[4] Nagayama Rheumatol & Orthopaed Clin, Higashi Ku, 4-3-25 Hiokisounishi Machi, Sakai, Osaka 5998114, Japan

[5] Toyonaka City Hosp, Dept Orthopaed Surg, 4-14-1 Shibahara Cho, Toyonaka, Osaka 5608565, Japan

[6] Osaka Toneyama Med Ctr, Dept Orthopaed Surg, 5-1-1 Toneyama, Toyonaka, Osaka 5608552, Japan

[7] Japan Community Hlth Care Org, Dept Orthopaed Surg, Osaka Hosp, 4-2-78 Fukushima, Osaka, Osaka 5530003, Japan

[8] Japan Community Hlth Care Org, Dept Orthopaed Surg, Hoshigaoka Med Ctr, 4-8-1 Hoshigaoka, Hirakata, Osaka 5738511, Japan

[9] Osaka Univ, Dept Hlth & Sport Sci, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan

来源：

BONE | 2020年 / 140卷

关键词：

Romosozumab; Prior treatment; Predictor; Bone turnover marker; Postmenopausal osteoporosis; TERIPARATIDE; WOMEN; ALENDRONATE;

D O I：

10.1016/j.bone.2020.115574

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose: To investigate the effects of prior treatment and the predictors of early treatment response to romosozumab (ROMO) in patients with postmenopausal osteoporosis. Methods: In this prospective, observational, multicenter study, 130 treatment-naive patients (Naive; n = 37) or patients previously treated with bisphosphonates (BP; n = 33), denosumab (DMAb; n = 45), or teriparatide (TPTD; n = 15) (age, 75.0 years; T-scores of the lumbar spine [LS] -3.2 and femoral neck [FN] -2.9) were switched to ROMO based on their physician's decision. Bone mineral density (BMD) and serum bone turnover markers were evaluated for six months. Results: At six months, LS BMD changes were 13.6%, 7.5%, 3.6%, and 8.7% (P < .001 between groups) and FN BMD changes were 4.2%, 0.4%, 1.6%, and 1.5% (P = .16 between groups) for Naive, BP, DMAb, and TPTD groups, respectively. Changes in N-terminal type I procollagen propeptide (PINP; mu g/L) levels from baseline -> one month were 72.7 -> 139.0, 33.5 -> 85.4, 30.4 -> 54.3, and 98.4 -> 107.4, and those of isoform 5b of tartrate-resistant acid phosphatase (TRACP-5b) (mU/dL) were 474.7 -> 270.2, 277.3 -> 203.7, 220.3 -> 242.0, and 454.1 -> 313.0 for Naive, BP, DMAb, and TPTD groups, respectively. Multivariate regression analysis revealed that significant predictors of LS BMD change at six months were prior treatment difference (r = -3.1, P = .0027) and TRACP-5b percentage change (r = -2.8, P = .0071) and PINP value at one month (r = 3.2, P = .0021). Conclusion: Early effects of ROMO on the increase in LS BMD are significantly affected by the difference of prior treatment and are predicted by the early change in bone turnover markers. Mini abstract: Early effects of ROMO on the increase in LS BMD at six months is significantly affected by the difference of prior treatment and also predicted by the early change of bone turnover markers in patients with postmenopausal osteoporosis.

引用

页数：6

共 20 条

[1] Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene [J].